These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32743578)

  • 1. Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.
    Zhao P; Praissman JL; Grant OC; Cai Y; Xiao T; Rosenbalm KE; Aoki K; Kellman BP; Bridger R; Barouch DH; Brindley MA; Lewis NE; Tiemeyer M; Chen B; Woods RJ; Wells L
    bioRxiv; 2020 Jul; ():. PubMed ID: 32743578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.
    Zhao P; Praissman JL; Grant OC; Cai Y; Xiao T; Rosenbalm KE; Aoki K; Kellman BP; Bridger R; Barouch DH; Brindley MA; Lewis NE; Tiemeyer M; Chen B; Woods RJ; Wells L
    Cell Host Microbe; 2020 Oct; 28(4):586-601.e6. PubMed ID: 32841605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2.
    Nguyen K; Chakraborty S; Mansbach RA; Korber B; Gnanakaran S
    Viruses; 2021 May; 13(5):. PubMed ID: 34067878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidating Interactions Between SARS-CoV-2 Trimeric Spike Protein and ACE2 Using Homology Modeling and Molecular Dynamics Simulations.
    Sakkiah S; Guo W; Pan B; Ji Z; Yavas G; Azevedo M; Hawes J; Patterson TA; Hong H
    Front Chem; 2020; 8():622632. PubMed ID: 33469527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.
    Mehdipour AR; Hummer G
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33903171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
    Rowland R; Brandariz-Nuñez A
    Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
    Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
    Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Importance of Glycosylation in COVID-19 Infection.
    Petrović T; Lauc G; Trbojević-Akmačić I
    Adv Exp Med Biol; 2021; 1325():239-264. PubMed ID: 34495539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycomics-informed glycoproteomic analysis of site-specific glycosylation for SARS-CoV-2 spike protein.
    Rosenbalm KE; Tiemeyer M; Wells L; Aoki K; Zhao P
    STAR Protoc; 2020 Dec; 1(3):100214. PubMed ID: 33377107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner.
    Isobe A; Arai Y; Kuroda D; Okumura N; Ono T; Ushiba S; Nakakita SI; Daidoji T; Suzuki Y; Nakaya T; Matsumoto K; Watanabe Y
    Commun Biol; 2022 Nov; 5(1):1188. PubMed ID: 36335195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins.
    Matthews AM; Biel TG; Ortega-Rodriguez U; Falkowski VM; Bush X; Faison T; Xie H; Agarabi C; Rao VA; Ju T
    PLoS One; 2022; 17(12):e0278294. PubMed ID: 36472974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
    Ali A; Vijayan R
    Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach.
    Zaheer M; Ali N; Javed H; Munir R; Jamil N
    J Infect Public Health; 2023 Oct; 16(10):1544-1555. PubMed ID: 37566991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data-independent acquisition mass spectrometry for site-specific glycoproteomics characterization of SARS-CoV-2 spike protein.
    Chang D; Klein JA; Nalehua MR; Hackett WE; Zaia J
    Anal Bioanal Chem; 2021 Dec; 413(29):7305-7318. PubMed ID: 34635934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-Specific Glycosylation Patterns of the SARS-CoV-2 Spike Protein Derived From Recombinant Protein and Viral WA1 and D614G Strains.
    Tian Y; Parsons LM; Jankowska E; Cipollo JF
    Front Chem; 2021; 9():767448. PubMed ID: 34869209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana.
    Castilho A; Schwestka J; Kienzl NF; Vavra U; Grünwald-Gruber C; Izadi S; Hiremath C; Niederhöfer J; Laurent E; Monteil V; Mirazimi A; Wirnsberger G; Stadlmann J; Stöger E; Mach L; Strasser R
    Biotechnol J; 2021 Jun; 16(6):e2000566. PubMed ID: 33481336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants.
    Dehghani J; Movafeghi A; Mathieu-Rivet E; Mati-Baouche N; Calbo S; Lerouge P; Bardor M
    Mar Drugs; 2022 Oct; 20(11):. PubMed ID: 36354980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.